- Home
- KALA vs KZR Comparison
KALA vs KZR Comparison
Compare KALA & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- KZR
- Stock Information
- Founded
- KALA 2009
- KZR 2015
- Country
- KALA United States
- KZR United States
- Employees
- KALA N/A
- KZR N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- KZR Health Care
- Exchange
- KALA Nasdaq
- KZR Nasdaq
- Market Cap
- KALA 26.2M
- KZR 29.7M
- IPO Year
- KALA 2017
- KZR 2018
- Fundamental
- Price
- KALA $1.67
- KZR $3.88
- Analyst Decision
- KALA Buy
- KZR Hold
- Analyst Count
- KALA 3
- KZR 2
- Target Price
- KALA $31.50
- KZR $9.00
- AVG Volume (30 Days)
- KALA 2.7M
- KZR 36.2K
- Earning Date
- KALA 11-11-2025
- KZR 11-11-2025
- Dividend Yield
- KALA N/A
- KZR N/A
- EPS Growth
- KALA N/A
- KZR N/A
- EPS
- KALA N/A
- KZR N/A
- Revenue
- KALA N/A
- KZR N/A
- Revenue This Year
- KALA N/A
- KZR N/A
- Revenue Next Year
- KALA N/A
- KZR N/A
- P/E Ratio
- KALA N/A
- KZR N/A
- Revenue Growth
- KALA N/A
- KZR N/A
- 52 Week Low
- KALA $1.10
- KZR $3.56
- 52 Week High
- KALA $20.60
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- KALA 27.87
- KZR 49.42
- Support Level
- KALA $1.26
- KZR $3.79
- Resistance Level
- KALA $1.69
- KZR $4.10
- Average True Range (ATR)
- KALA 1.14
- KZR 0.22
- MACD
- KALA -1.93
- KZR 0.02
- Stochastic Oscillator
- KALA 2.80
- KZR 61.44
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.